Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700023107

Trial Profile

Clinical Trials Insight: 700023107

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2008

At a glance

  • Drugs NGD 4715 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Neurogen Corporation
  • Most Recent Events

    • 14 Jan 2008 Based on results from the multiple dose ascending study, Neurogen has decided not to advance NGD 4715 into phase II testing, but will consider out-licensing its drug program for potential development with a partner.
    • 11 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top